We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
+29.19%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$501M
AUM Growth
+$82.2M
Cap. Flow
-$73.5M
Cap. Flow %
-14.69%
Top 10 Hldgs %
69.75%
Holding
49
New
6
Increased
15
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
EVCM icon
EverCommerce
EVCM
+$16M
2
ENGN icon
enGene Therapeutics
ENGN
+$15M
3
SGMT icon
Sagimet Biosciences
SGMT
+$9.47M
4
BRZE icon
Braze
BRZE
+$5.31M
5
LRMR icon
Larimar Therapeutics
LRMR
+$4.52M

Top Sells

Rank Stock Value
1
TOST icon
Toast
TOST
+$115M
2
KROS icon
Keros Therapeutics
KROS
+$10.7M
3
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$7.97M
4
CGEM icon
Cullinan Oncology
CGEM
+$7.65M
5
BPMC
Blueprint Medicines
BPMC
+$6.63M

Sector Composition

Rank Sector Weight
1 Healthcare 66.92%
2 Financials 17.24%
3 Technology 14.42%
4 Industrials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LABD icon
26
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$39.8M
$3.57M 0.71%
49,000
+15,000
+44% +$1.25M
MDGL icon
27
Madrigal Pharmaceuticals
MDGL
$11.8B
$3.56M 0.71%
+13,319
New +$3.14M
BDTX icon
28
Black Diamond Therapeutics
BDTX
$112M
$3.52M 0.7%
695,000
– –
ADCT icon
29
ADC Therapeutics
ADCT
$144M
$3.29M 0.66%
733,568
– –
IMVT icon
30
Immunovant
IMVT
$8.25B
$3.23M 0.65%
100,000
+40,000
+67% +$1.46M
ENGNW icon
31
enGene Therapeutics Warrants
ENGNW
$2.66M 0.53%
511,177
+36,100
+8% +$110K
OVID icon
32
Ovid Therapeutics
OVID
$491M
$2.64M 0.53%
864,822
– –
BRZE icon
33
Braze
BRZE
$2.99B
$2.36M 0.47%
116,153
+98,427
+555% +$5.31M
SYRS
34
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.82M 0.36%
340,855
-1,152,397
-77% -$7.97M
SNOW icon
35
Snowflake
SNOW
$115B
$1.26M 0.25%
+7,819
New +$1.52M
GTLB icon
36
GitLab
GTLB
$6.58B
$1.21M 0.24%
+20,706
New +$1.36M
BLND icon
37
Blend Labs
BLND
$386M
$1.18M 0.23%
361,587
– –
GOCO
38
DELISTED
GoHealth
GOCO
$875K 0.17%
83,264
– –
DM
39
DELISTED
Desktop Metal, Inc.
DM
$660K 0.13%
75,000
– –
RLYB icon
40
Rallybio
RLYB
$85.8M
$648K 0.13%
43,780
– –
ELVN icon
41
Enliven Therapeutics
ELVN
$4.43B
$440K 0.09%
+25,000
New +$384K
DTIL icon
42
Precision BioSciences
DTIL
$207M
$274K 0.05%
20,220
-1
-0% -$12
FATH
43
DELISTED
Fathom Digital Manufacturing Corporation
FATH
$231K 0.05%
50,000
– –
UBER icon
44
Uber
UBER
$153B
$78.9K 0.02%
23,918
+17,731
+287% +$1.27M
BPMC
45
DELISTED
Blueprint Medicines
BPMC
– –
-71,888
Closed -$6.63M
MIRM icon
46
Mirum Pharmaceuticals
MIRM
$6.14B
– –
-10,013
Closed -$296K
PLMJW
47
DELISTED
Plum Acquisition Corp. III Warrant
PLMJW
$0 ﹤0.01%
666,666
– –
FRLN
48
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
– –
-86,654
Closed -$552K
ORTX
49
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-1,599,660
Closed -$2.63M
1
2

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
JC
Joho Capital New York $373M AUM 18.89% 1-Year Est. Return

Blue Owl Capital Holdings's Q1 2024 Portfolio in Review

As of Q1 2024, Blue Owl Capital Holdings held 49 positions worth $501M, up 20% from $418M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Blue Owl Capital Holdings withdrew a net $73.5M in Q1 2024, closing 4 positions and reducing 6 holdings. Its most notable exit was Blueprint Medicines, an estimated $6.63M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 67% a quarter earlier, followed by Financials and Technology.

Against the trend, Blue Owl Capital Holdings opened a new position in EverCommerce worth $15.5M.

  • Blue Owl Capital Holdings's largest Q1 2024 buy was EverCommerce: 1,641,929 shares worth $15.5M.
  • Blue Owl Capital Holdings added most to enGene Therapeutics in Q1 2024, an estimated $15M increase.
  • Blue Owl Capital Holdings's biggest Q1 2024 reduction was Toast, cutting an estimated $115M.
  • Blue Owl Capital Holdings fully exited Blueprint Medicines in Q1 2024, selling an estimated $6.63M.
  • Blue Owl Capital Holdings's ten largest holdings make up 70% of its $501M portfolio in Q1 2024.
  • Blue Owl Capital Holdings opened 6 new positions and closed 4 in Q1 2024.
  • Blue Owl Capital Holdings's portfolio value rose 20% quarter-over-quarter to $501M.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2024, filed 15 May 2024.